Chapter 7 Clinical Relevance of BNP Measurement in the Follow-Up of Patients with Chronic Heart Failure

Advances in Clinical Chemistry

Volumn 48, Issue , 2009, Pages 163-179

  Clerico, Aldo ^a,b   Fontana, Marianna ^a   Ripoli, Andrea ^a   Emdin, Michele ^a  

^a FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^b SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

BNP; Cardiac natriuretic peptides; Clinical trials; Heart failure; Meta analysis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; ARTICLE; BLOOD; CHRONIC DISEASE; HEART FAILURE; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

AGE FACTORS; CHRONIC DISEASE; HEART FAILURE; HUMANS; META-ANALYSIS AS TOPIC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS;

EID: 69549111749     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(09)48007-7     Document Type: Review

References (62)

1. NICE (National Institute of Clinical Excellence). Clinical Guideline 5. chronic heart failure. Management of chronic heart failure in adults in primary and secondary care (July 2003) 1-44 London
2. Swedberg K., Cleland J., Dargie H., et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J. 26 (2005) 1115-1140
3. Nieminen M.S., Böhm M., Cowie M.R., et al. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J. 26 (2005) 384-416
4. Hunt S.A. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 46 (2005) e1-e82
5. Adams K.F., Lindenfeld J., Arnold J.M.O., Baker D.W., Barnard D.H., and Baughman K.L. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J. Card. Fail. 12 (2006) 10-38
6. Braunwald E., and Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 102 20 Suppl. 4 (2000) IV14-IV23
7. Emdin M., Vittorini S., Passino C., and Clerico A. Old and new biomarkers of heart failure. Eur. J. Heart Fail. 11 (2009) 331-335
8. Clerico A., Recchia F.A., Passino C., and Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H17-H29
9. Balion C.M., Santaguida P., McKelvie R., et al. Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP. Clin. Biochem. 41 (2008) 231-239
10. Clerico A., and Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin. Chem. 50 (2004) 33-50
11. Doust J.A., Glasziou P.P., Pietrzak E., and Dobson A.J. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch. Intern. Med. 164 (2004) 1978-1984
12. Clerico A., Fontana M., Zyw L., Passino C., and Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin. Chem. 53 (2007) 813-822
13. Balion C.M., McKelvie R.S., Reichert S., et al. Monitoring the response to pharmacologic therapy in patients with stable chronic heart failure: is BNP or NT-proBNP a useful assessment tool?. Clin. Biochem. 41 (2008) 266-276
14. Ewald B., Ewald D., Thakkinstian A., and Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern. Med. J. 38 (2008) 101-113
15. Emdin M., Passino C., Prontera C., et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal proBNP for early diagnosis of heart failure. Clin. Chem. 53 (2007) 1264-1272
16. Tang W.H., Francis G.S., Morrow D.A., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109
17. Ramos H., and de Bold A.J. Gene expression, processing, and secretion of natriuretic peptides: physiologic and diagnostic implications. Heart Fail. Clin. 2 (2006) 255-268
18. De Bold A.J. Cardiac natriuretic peptides gene expression and secretion in inflammation. J. Investig. Med. 57 (2009) 29-32
19. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90 (1994) 195-203
20. Sawada Y., Suda M., Yokoyama H., et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J. Biol. Chem. 272 (1997) 20545-20554
21. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin. Chem. 50 (2004) 1503-1510
22. Schellenberger U., O'Rear J., Guzzetta A., Jue R.A., Protter A.A., and Pollitt N.S. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch. Biochem. Biophys. 451 (2006) 160-166
23. Luckenbill K.N., Christenson R.H., Jaffe A.S., et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC committee for standardization of markers of cardiac damage. Clin. Chem. 54 (2008) 619-620
24. Clerico A., Del Ry S., and Giannessi D. Measurement of natriuretic cardiac hormones (ANP, BNP and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin. Chem. 46 (2000) 1529-1534
25. Panteghini M., and Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin. Lab. 50 (2004) 325-331
26. Apple F.S., Panteghini M., Ravkilde J., et al. On Behalf of the Committee on Standardization of Markers of Cardiac Damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin. Chem. 51 (2005) 486-493
27. Apple F.S., Wu A.H., Jaffe A.S., et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 116 (2007) e95-e98
28. Vittorini S., Prontera T., Zucchelli G.C., and Clerico A. Cardiac natriuretic hormones: methodological aspects. Immuno-Analyse Biol. Spec. 22 (2007) 209-272
29. Prontera C., Zucchelli C.G., Vittorini S., Storti S., Emdin M., and Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin. Chim. Acta 400 (2009) 70-73
30. Prontera C., Zaninotto M., Giovannini S., et al. Proficiency testing project for BNP and NT-proBNP immunoassays: the CardioOrmocheck study. Clin. Chem. Lab. Med. 47 (2009) 762-768
31. Richards A.M., Lainchbury J.G., Nicholls M.G., Troughton R.W., and Yandle T.G. BNP in hormone-guided treatment of heart failure. Trends Endocrinol. Metab. 13 (2002) 151-155
32. Clerico A., Vittorini S., Passino C., and Emdin M. New biomarkers of heart failure. Crit. Rev. Cl. Lab. Sci. 46 (2009) 107-128
33. Anand I.S., Fisher L.D., Chiang Y.T., et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
34. Richards A.M., Doughty R., Nicholls M.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J. Am. Coll. Cardiol. 37 (2001) 1781-1787
35. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J. 138 (1999) 1126-1132
36. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
37. Kawai K., Hata K., Takaoka H., Kawai H., and Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am. Heart J. 141 (2001) 925-932
38. Nicholls M.G., Lainchbury J.G., Richards A.M., Troughton R.W., and Yandle T.G. Brain natriuretic peptide-guided therapy for heart failure. Ann. Med. 33 (2001) 422-427
39. Troughton R.W., Richards A.M., and Nicholls M.G. Individualized treatment of heart failure. Intern. Med. J. 31 (2001) 138-141
40. McGeoch G., Lainchbury J., Town G.I., Toop L., Espiner E., and Richards A.M. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur. J. Heart Fail. 4 (2002) 479-483
41. Crozier I.G., Nicholls M.G., Ikram H., Espiner E.A., and Yandle T.G. Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin. Exp. Pharmacol. Physiol. 16 (1989) 417-424
42. Yoshimura M., Yasue H., Tanaka H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br. Heart J. 72 (1994) 528-533
43. Davidson N.C., Coutie W.J., Webb D.J., and Struthers A.D. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart 75 (1996) 576-581
44. Nishikimi T., Matsuoka H., Ishikawa K., et al. Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. Hypertens. Res. 19 (1996) 97-101
45. Missouris C.G., Grouzmann E., Buckley M.G., Barron J., MacGregor G.A., and Singer D.R. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin. Sci. 94 (1998) 591-599
46. Hara Y., Hamada M., Shigematsu Y., et al. Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn. Circ. J. 64 (2000) 365-369
47. Tsutamoto T., Wada A., Maeda K., et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37 (2001) 1228-1233
48. Johnson W., Omland T., Hall C., et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol. 39 (2002) 1623-1629
49. Latini R., Masson S., Anand I., et al. Valsartan Heart Failure Trial Investigators. Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
50. Latini R., Masson S., de Angelis N., and Anand I. Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. (Review) J. Card. Fail. 8 (2002) 288-299
51. Bettencourt P., Azevedo A., Pimenta J., Friões F., Ferreira S., and Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004) 2168-2174
52. Yan R.T., White M., Yan A.T., et al. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am. J. Cardiol. 96 (2005) 698-704
53. Latini R., Masson S., Wong M., et al. Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am. J. Med. 119 70 (2006) e23-e30
54. Masson S., Latini R., Anand I.S., et al. Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J. Am. Coll. Cardiol. 52 (2008) 997-1003
55. Rosenberg J., Gustafsson F., Remme W.J., Riegger G.A., and Hildebrandt P.R. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc. Drugs Ther. 22 (2008) 305-311
56. Waldo S.W., Beede J., Isakson S., et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J. Am. Coll. Cardiol. 51 (2008) 1874-1882
57. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49 (2007) 1733-1739
58. Pfisterer M., Buser P., Rickli H., et al. TIME-CHF Investigators. BNP guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 (2009) 383-392
59. Eurlings L., van Wijk S., Balk A., et al. Can pro-brain natriuretic peptide guided therapy of heart failure improve heart failure morbidity and mortality?. main Outcome of the PRIMA-Study. Presented to ACC Congress, Orlando (March 29th 2009). http://assets.cardiosource.com/PRIMA_Eurlings.ppt Presentation number 402-14, available online at
60. Richards A.M., Lainchbury J.G., Troughton R.W., et al. Abstract 5946: NTproBNP guided treatment for chronic heart failure: results from the Battlescarred Trial. Circulation 118 (2008) S1035-S1036
61. Faul F., Erdfelder E., Lang A.G., and Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 3 (2007) 175-191
62. Reny J.L., Millot O., Vanderecamer T., et al. Admission NT-proBNP levels, renal insufficiency and age as predictors of mortality in elderly patients hospitalized for acute dyspnea. Eur. J. Intern. Med. 20 (2009) 14-19